State Street SPDR S&P Pharmaceuticals ETF
XPH
78 hedge funds and large institutions have $149M invested in State Street SPDR S&P Pharmaceuticals ETF in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
13% more funds holding
Funds holding: 69 → 78 (+9)
5% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 22
1.64% less ownership
Funds ownership: 33.05% → 31.41% (-1.6%)
11% less capital invested
Capital invested by funds: $167M → $149M (-$18.7M)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $687K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$8.02M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6.57M |
| 3 |
IAA
Ironsides Asset Advisors
Rocky Mount,
North Carolina
|
+$2.87M |
| 4 |
Citigroup
New York
|
+$2.62M |
| 5 |
RCM
RNC Capital Management
Los Angeles,
California
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$9.76M |
| 2 |
Goldman Sachs
New York
|
-$8.61M |
| 3 |
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet
Tel Aviv,
Israel
|
-$4.75M |
| 4 |
CCMD
Cypress Capital Management (Delaware)
Greenville,
Delaware
|
-$1.88M |
| 5 |
KHLMTHM
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Tel Aviv,
Israel
|
-$1.85M |
XPH Hedge Fund Activity: Q4 2016 in Review
78 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2016, worth a combined $149M — down 11% from $167M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new XPH positions and 10 closed out — a net gain of 10 holders — while 21 added to existing stakes and 22 trimmed.
The largest buyer was UBS Group, adding an estimated $8.02M. The largest seller was Psagot Value Holdings, cutting an estimated $9.76M.
- 78 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2016, up from 69 in Q3 2016.
- Funds reported $149M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2016, down 11% quarter-over-quarter.
- 20 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2016 and 10 closed out, a net change of +10 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2016 was UBS Group, an estimated $8.02M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2016 was Psagot Value Holdings, an estimated $9.76M sold.
Based on aggregated 13F filings for Q4 2016.